The pharmaceutical company Sanofi made profits of 8,614 million euros in the first nine months of the year, an increase of 70.2% compared to the same period last year, the company said today.
A large part of the profit is explained by the sale of Opella.
The French pharmaceutical company explains, in a statement, that the net result of its activities, which excludes non-recurring elements unrelated to its operation, grew by 5.9% in absolute values and 9.8% in comparable values, reaching 7,699 million euros.
The operating result, in turn, increased by 5.9% in gross data and 9.7% in equivalents, reaching 9,808 million euros, and turnover increased by 5.9%, reaching 32,323 million euros.
Considering only the third quarter, Sanofi obtained a profit of 2,802 million euros, a decrease of 0.5% compared to the same period in 2024, although the operating result of activities increased by 2.7% in absolute values and 8.5% in comparable values, to 4,445 million.
Quarterly turnover increased by 2.3% in gross terms and 7% in comparable terms, reaching 12,434 million euros.
Referring to these three months, the executive president, Paul Hudson, highlighted that sales of new pharmaceutical launches increased by 40.8%.
Sales of its product Dupixent (used in particular to treat asthma and other respiratory diseases) exceeded four billion euros for the first time worldwide and three billion in the United States alone, he said.
The company guaranteed that it will maintain its financial outlook for the entire year unchanged.
Net earnings per share from activities increased by 13.2% in the third quarter, to 2.91 euros. In the first nine months of the financial year, the increase was 12.4%, to 6.30 euros.
The post Profits Grow 70% with Opella Sales appeared first on Veritas News.
